Canary Capital has established a Delaware trust for a potential Injective (INJ) staking exchange-traded fund (ETF), signaling heightened institutional interest in cryptocurrency staking products despite ongoing regulatory questions. The trust filing represents a preliminary step toward launching an ETF that would provide investors with combined exposure to INJ token ownership and staking rewards.
Staking-based ETFs are gaining market traction by offering dual benefits of potential price appreciation and yield generation. This development follows European asset manager 21Shares’ existing offering of similar staking products, reflecting growing industry momentum.
The announcement triggered immediate market reaction, with INJ’s price rising 3.7% within 24 hours. The token has gained over 10.5% in weekly trading amid increased on-chain activity, demonstrating investor optimism toward the proposed financial instrument.
Regulatory hurdles remain significant as the U.S. Securities and Exchange Commission (SEC) has raised compliance concerns regarding whether staking ETFs meet securities law requirements. Despite these challenges, industry analysts express confidence that regulatory solutions will emerge to facilitate such products.
Injective’s broader appeal to institutional and retail investors stems from its focus on artificial intelligence-powered trading agents and real-world asset tokenization, positioning the blockchain platform at the intersection of multiple technological innovations.